Evaluation of Conjunctival Autografting Augmented with Mitomycin C Application
Journal
Journal of ophthalmology
ISSN: 2090-004X
Titre abrégé: J Ophthalmol
Pays: United States
ID NLM: 101524199
Informations de publication
Date de publication:
2021
2021
Historique:
received:
14
08
2020
revised:
08
12
2020
accepted:
03
01
2021
entrez:
28
1
2021
pubmed:
29
1
2021
medline:
29
1
2021
Statut:
epublish
Résumé
To evaluate the safety and efficacy of augmenting conjunctival autografting with intraoperative mitomycin C (MMC) application This prospective randomised study included 63 eyes of 63 patients, with recurrent nasal pterygium, who presented to the outpatient clinic of Menoufia University Hospital in Shebin El Kom and Manshiet Soltan from January 2016 to December 2019. Patients were randomly enrolled into two groups. Group A included 32 eyes of 32 patients who underwent conjunctival autografting augmented with the topical application of MMC (0.2 mg/mL), and group B included 31 eyes of 31 patients who underwent conjunctival autografting augmented with Ologen implantation. All the patients underwent follow-up examinations for a period of 24 months. During each visit, a complete ophthalmic examination was performed. Pterygium regrowth of 1 mm or more, over the cornea, was considered a recurrence. In the MMC group, no recurrence was reported during the 24-month follow-up period. In the Ologen implantation group, recurrence was reported in 2 (8%) eyes. The time interval from surgery to recurrence was 5 months in one case and 8 months in the other. No other serious postoperative complications were reported, and there was no statistically significant difference between the groups in this regard. Ologen implantation with conjunctival autografting shows promising results in the surgical management of recurrent pterygium with mild non-vision-threatening postoperative complications comparable to that of MMC application with conjunctival autografting. Registration number:
Identifiants
pubmed: 33505715
doi: 10.1155/2021/8820926
pmc: PMC7815381
doi:
Banques de données
ClinicalTrials.gov
['NCT04419038']
Types de publication
Journal Article
Langues
eng
Pagination
8820926Informations de copyright
Copyright © 2021 Faried M. Wagdy et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.
Références
BMC Ophthalmol. 2012 Aug 08;12:38
pubmed: 22873737
Ophthalmology. 2009 Jul;116(7):1278-86
pubmed: 19576496
Ocul Surf. 2014 Apr;12(2):112-9
pubmed: 24725323
Ophthalmology. 1999 Apr;106(4):817-21
pubmed: 10201608
Acta Ophthalmol (Copenh). 1994 Dec;72(6):721-6
pubmed: 7747583
BMC Ophthalmol. 2018 Sep 20;18(1):254
pubmed: 30236087
Am J Ophthalmol. 1995 Aug;120(2):151-60
pubmed: 7639298
Br J Ophthalmol. 2000 Sep;84(9):973-8
pubmed: 10966947
Ophthalmology. 1998 May;105(5):901-4; discussion 904-5
pubmed: 9593395
Ophthalmology. 2002 Sep;109(9):1752-5
pubmed: 12208727
J Ocul Pharmacol Ther. 2013 Apr;29(3):330-4
pubmed: 23113645
Eye (Lond). 2010 Sep;24(9):1449-57
pubmed: 20733558
Ophthalmic Surg Lasers. 2000 Jul-Aug;31(4):301-7
pubmed: 10928667
Ophthalmic Surg Lasers. 1997 Feb;28(2):99-104
pubmed: 9054479
Curr Opin Ophthalmol. 2007 Jul;18(4):308-13
pubmed: 17568207
Cornea. 1994 Sep;13(5):411-3
pubmed: 7995063
Invest Ophthalmol Vis Sci. 2000 Aug;41(9):2404-11
pubmed: 10937547
Ophthalmology. 2003 Jun;110(6):1126-36
pubmed: 12799236
J Cataract Refract Surg. 2017 Mar;43(3):405-419
pubmed: 28410726
Br J Ophthalmol. 2006 Dec;90(12):1476-80
pubmed: 16837545
Am J Ophthalmol. 2011 Nov;152(5):730-2
pubmed: 21742307
Cornea. 2003 Oct;22(7):598-603
pubmed: 14508255
Clin Ophthalmol. 2014 Jun 13;8:1105-18
pubmed: 24966664
Ophthalmology. 1992 Nov;99(11):1647-54
pubmed: 1454338
Clin Exp Ophthalmol. 2006 Apr;34(3):197-8
pubmed: 16671897